Art

J-GLOBAL ID：202002233248278665   Reference number：20A2684932

Evaluation of Proteinuria Using Urine Protein : Creatine Ratio in Treatment with Molecular Targeted Agents for Advanced Renal Cell Carcinoma

尿蛋白質を用いた蛋白尿の評価:進行腎細胞癌に対する分子標的薬治療におけるクレアチン比

Author (7)： Nakamura Katsuyuki (Division of Hospital Pharmacy, Sapporo Medical University) ,  Nakamura Katsuyuki (Department of Practical Pharmacy, School of Pharmaceutical Sciences, Health Sciences University of Hokkaido) ,  Tanaka Toshiaki (Department of Urology, School of Medicine, Sapporo Medical University) ,  Masumori Naoya (Department of Urology, School of Medicine, Sapporo Medical University) ,  Miyamoto Atsushi (Division of Hospital Pharmacy, Sapporo Medical University) ,  Miyamoto Atsushi (Division of Pharmaceutical Health Care and Sciences, School of Medicine, Sapporo Medical University) ,  Hirano Takeshi (Department of Practical Pharmacy, School of Pharmaceutical Sciences, Health Sciences University of Hokkaido)
Material： Biological and Pharmaceutical Bulletin (Web)
Volume： 43  Issue： 10  Page： 1506-1510(J-STAGE)  Publication year： 2020 
JST Material Number： U1402A  ISSN： 1347-5215  Document type： Article
Article type： 原著論文  Country of issue： Japan (JPN)  Language： ENGLISH (EN)

Thesaurus term： human(primates) ,...
Semi thesaurus term： ディップスティック試験 ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=20A2684932&from=J-GLOBAL&jstjournalNo=U1402A") }}

Author keywords (8)： molecular targeted drug therapy ,  renal cell carcinoma ,  proteinuria ,  urine protein : creatine ratio ,  molecular targeted drug therapy ,  renal cell carcinoma ,  proteinuria ,  urine protein : creatine ratio

JST classification (2)： Urogenital tumors(=neoplasms)  (GM04000S) ,  Drug therapy(=pharmacotherapy)for tumors  (GE03032C)

Substance index (5)： Axitinib ,  Everolimus ,  Creatine ,  Sunitinib ,  Sorafenib

Reference (24)：

• 1) Hara A, Wada T, Furuichi K, Sakai N, Kawachi H, Shimizu F, Shibuya M, Matsushima K, Yokoyama H, Egashira K, Kaneko S. Blockade of VEGF accelerates proteinuria, via decrease in nephrin expression in rat crescentic glomerulonephritis. Kidney Int., 69, 1986-1995 (2006).
• 2) Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, Richardson C, Kopp JB, Kabir MG, Backx PH, Gerber HP, Ferrara N, Barisoni L, Alpers CE, Quaggin SE. VEGF inhibition and renal thrombotic microangiopathy. N. Engl. J. Med., 358, 1129-1136 (2008).
• 3) Izzedine H, Mangier M, Ory V, Zhang SY, Sendeyo K, Bouachi K, Audard V, Péchoux C, Soria JC, Massard C, Bahleda R, Bourry E, Khayat D, Baumelou A, Lang P, Ollero M, Pawlak A, Sahali D. Expression patterns of RelA and c-mip are associated with different glomerular diseases following anti-VEGF therapy. Kidney Int., 85, 457-470 (2014).
• 4) Ginsberg JM, Chang BS, Matarese RA, Garella S. Use of single voided urine samples to estimate quantitative proteinuria. N. Engl. J. Med., 309, 1543-1546 (1983).
• 5) Schwab SJ, Christensen RL, Dougherty K, Klahr S. Quantitation of proteinuria by the use of protein-to-creatinine ratios in single urine samples. Arch. Intern. Med., 147, 943-944 (1987).

Terms in the title (7)： 尿蛋白質 ,  蛋白尿 ,  評価 ,  進行腎細胞癌 ,  分子標的薬 ,  治療 ,  クレアチン